Exploring survival and gene mutations in lung cancer staging
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Fudan University · NCT06349252
This study looks at how certain gene changes and survival rates in lung cancer patients with specific disease stages can help doctors understand and improve treatment outcomes after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1263 (estimated) |
| Sex | All |
| Sponsor | Fudan University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06349252 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the survival outcomes and gene mutations associated with the N descriptors in the ninth edition of the TNM classification system for non-small cell lung cancer. It focuses on patients with pathological N2 status and examines how these factors correlate with stage grouping and overall survival. The study involves radical resection as the primary intervention to assess the impact of the new classification on patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with non-small cell lung cancer who have pathological N2 status.
Not a fit: Patients undergoing neoadjuvant chemotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of lung cancer staging and improve treatment strategies for patients with non-small cell lung cancer.
How similar studies have performed: While this study explores a new classification system, similar studies have previously shown the importance of staging in predicting outcomes in lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Pathological N2. Exclusion Criteria: Patients undergoing neoadjuvant chemotherapy
Where this trial is running
Shanghai, Shanghai
- Fudan University Cancer Center — Shanghai, Shanghai, China (RECRUITING)
Study contacts
- Study coordinator: Fangqiu Fu, MD
- Email: fufangqiu12@163.com
- Phone: +86-13122677592
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-small Cell Lung Cancer